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Summary
 
It is widely accepted that immunoglobulin (Ig)E triggers immediate hypersensitivity responses
by activating a cognate high-affinity receptor, Fc
 
e
 
RI, leading to mast cell degranulation with
release of vasoactive and proinflammatory mediators. This apparent specificity, however, is
complicated by the ability of IgE to bind with low affinity to Fc receptors for IgG, Fc
 
g
 
RII and
III. We have addressed the in vivo significance of this interaction by studying IgE-mediated
passive systemic anaphylaxis in Fc
 
g
 
R-deficient mice. Mice deficient in the inhibitory receptor
for IgG, Fc
 
g
 
RIIB, display enhanced IgE-mediated anaphylactic responses, whereas mice defi-
cient in an IgG activation receptor, Fc
 
g
 
RIII, display a corresponding attenuation of IgE-medi-
ated responses. Thus, in addition to modulating IgG-triggered hypersensitivity responses, Fc
 
g
 
RII
and III on mast cells are potent regulators of IgE-mediated responses and reveal the existence of
a regulatory pathway for IgE triggering of effector cells through IgG Fc receptors that could
contribute to the etiology of the atopic response.
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T
 
he anaphylaxis reaction in mice has been considered to
be a typical immediate hypersensitivity response deter-
mined primarily by the activation of mast cells via antigen-
induced aggregation of an IgE-sensitized high-affinity recep-
tor for IgE (Fc
 
e
 
RI),
 
1
 
 causing the release of potent systemic
mediators (1, 2). The central role of Fc
 
e
 
RI in mediating the
response was demonstrated by observations that mice defi-
cient in this receptor fail to undergo IgE-dependent, passive
cutaneous (3) and passive systemic anaphylaxis (4). These re-
sults were interpreted as indicating a necessary and sufficient
role for Fc
 
e
 
RI in mediating the IgE-dependent anaphylactic
response, excluding the possibility for involvement of other
potential receptors for IgE (5). However, earlier observa-
tions indicated that the low-affinity Fc receptors for IgG
(Fc
 
g
 
RIIB and Fc
 
g
 
RIII) on mouse mast cells, macrophages,
and the rat mucosal type mast cell RBL-2H3 can bind IgE
immune complexes in vitro (6, 7), and the engagement of
Fc
 
g
 
RIIB/III with IgE immune complexes triggers C57.1
mast cells to release serotonin (6), suggesting a greater poten-
tial complexity to the IgE-mediated anaphylactic response.
Studies on active anaphylaxis in gene-targeted mice fur-
ther challenged the simple model of IgE and Fc
 
e
 
RI as the
sole initiators of anaphylaxis and revealed a critical role for
IgG and Fc
 
g
 
R in this response. Induction of active anaphy-
laxis in mice deficient in IgE indicated that IgE antibodies
were not essential for the expression of systemic anaphylaxis
(8). In addition, mice deficient in Fc
 
e
 
RI mounted an undi-
minished active systemic anaphylactic response, whereas ac-
tive sensitization and challenge of animals deficient in the
common 
 
g
 
 chain (FcR
 
g
 
2
 
/
 
2
 
) resulted in protection (9, 10).
Further support for the conclusion that type I immediate
hypersensitivity has a significant dependence on IgG1 and
 
Fc
 
g
 
Rs came from studies demonstrating that Fc
 
g
 
RIIB-
deficient (Fc
 
g
 
RIIB
 
2
 
/
 
2
 
) mice exhibited an enhanced reac-
tion in IgG1-mediated passive cutaneous anaphylaxis, thereby
 
1
 
Abbreviations used in this paper:
 
 BMMC, bone marrow–derived cultured
mast cells; Fc
 
e
 
RI, high-affinity receptor for IgE; Fc
 
g
 
R, Fc receptor for
IgG; FcR
 
g
 
, Fc receptor 
 
g 
 
subunit; Fc
 
g
 
RIIB and Fc
 
g
 
RIII, type IIB and
type III low-affinity receptors for IgG, respectively.  
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establishing the importance of Fc
 
g
 
RIIB as an inhibitory
receptor under physiologic conditions (11), as suggested
previously in extensive in vitro studies by Daëron and col-
leagues (12, 13; for review see reference 14).
Although the evidence supporting a direct role for IgG
and Fc
 
g
 
Rs in the anaphylaxis reaction is compelling, the
contribution of these receptors to the canonical IgE-medi-
ated response is generally considered to be minimal. To di-
rectly analyze the roles of Fc
 
g
 
RIIB and Fc
 
g
 
RIII in the
IgE-dependent component of the systemic anaphylaxis re-
action, we compared the responses elicited in Fc
 
g
 
RIIB
 
2
 
/
 
2
 
and Fc
 
g
 
RIII
 
2
 
/
 
2
 
 mice upon passive transfer of either anti-
TNP IgE or IgG followed by intravenous challenge with
TNP-OVA. As expected, Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 and Fc
 
g
 
RIII
 
2
 
/
 
2
 
 mice
displayed enhanced or attenuated systemic anaphylaxis to
IgG1 sensitization, respectively. However, contrary to the
accepted dogma, intense modulation of IgE-dependent sys-
temic anaphylaxis was also observed in these Fc
 
g
 
R
 
2
 
/
 
2
 
 mice
as a result of the low-affinity interactions of IgE–antigen
complexes with these receptors. These studies demonstrate
the in vivo physiological significance of low-affinity IgE in-
teractions with Fc
 
g
 
Rs and represent a novel regulatory path-
way for classical type I hypersensitivity responses.
 
Materials and Methods
 
Antibodies.
 
Rat anti–mouse Fc
 
g
 
RIIB/III (2.4G2; PharMingen)
and mouse anti-TNP IgE (IGELa2; American Type Culture Col-
lection) and anti-TNP IgG1 (G1; 15) were purified from the as-
cites of hybridomas by ion exchange chromatography on DEAE–
cellulose (Merck) (16) and by affinity isolation with protein G
column (17), followed by removal of aggregated materials by ul-
tracentrifugation at 130,000 
 
g
 
 for 90 min at 20
 
8
 
C.
 
Animals.
 
All experiments were performed on 6–12-wk-old
mice. Male and female Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 (11) or Fc
 
g
 
RIII
 
2
 
/
 
2
 
 mice (Y.
Ishikawa, J.V. Ravetch, and T. Takai, unpublished results) were
generated by breeding the F2 offspring of crosses between chime-
ras and C57BL/6 mice, and the wild-type mice generated by the
same breeding protocol were used as wild-type animals. Fc
 
g
 
R
 
2
 
/
 
2
 
mice were generated as described previously (3) and back-crossed
to C57BL/6 background over six generations. Fc
 
g
 
RIII
 
2
 
/
 
2
 
 mice
were generated using RW4 embryonic stem cells (GenomeSys-
tems Inc.) as described previously (3, 11). Mice were housed in
cages in cabinets supplied with high efficiency particulate-free air
and were monitored monthly as specific pathogen free.
 
Induction of Passive Systemic Anaphylaxis.
 
Mouse IgG1 or IgE
anti-TNP mAbs were administered intravenously through the tail
vein in volumes of 
 
z
 
200 
 
m
 
l/mouse. 30 min after injection of
anti-TNP IgG1 or 24 h after injection of IgE, mice were injected
with 1.0 mg i.v. TNP
 
4
 
-OVA in PBS. Control mice received
OVA in PBS instead. The concentration of IgG1 and IgE mAbs
used for passive sensitization and the amount of TNP-OVA used
for challenge was determined based on preliminary dose–response
experiments required to produce significant drops in body tem-
perature in wild-type and Fc
 
g
 
RIIB
 
2
 
/
 
2
 
 or Fc
 
g
 
RIII
 
2
 
/
 
2
 
 mice. Al-
ternatively, systemic anaphylaxis was induced by the intravenous
injection of 10 
 
m
 
g 2.4G2 in 200 
 
m
 
l PBS. The amount was deter-
mined based on the preliminary dose–response experiment in the
same way described above. In a blocking experiment in Fc
 
g
 
RIII
 
2
 
/
 
2
 
mice, 100 
 
m
 
g 2.4G2 was administered.
 
Monitoring of Rectal Temperature and Heart Rate.
 
Changes in core
body temperature associated with systemic anaphylaxis were
monitored by measuring changes in rectal temperature using a
rectal probe coupled to a digital thermometer (Natsume Sei-
sakusyo Co.) as described (4, 9, 10). Heart rate was recorded as
electrocardiograms (Nihon Kohden) of mice under 2,2,2-tribro-
moethanol (0.25 mg/g body weight, i.p.) anesthesia.
 
Flow Cytometric Analysis.
 
Bone marrow–derived cultured mast
cells (BMMC) were prepared as described previously (3). For
monitoring of upregulation of Fc
 
e
 
RI protein on BMMC mem-
brane, cells were cultured in the presence of 0.1 or 5 
 
m
 
g/ml bio-
tinylated IgE or 5 
 
m
 
g/ml biotinylated 2.4G2 for 4 d before final
staining with biotinylated IgE (5 
 
m
 
g/ml) plus PE-conjugated
streptavidin. Peritoneal resident cells were collected by washing
with Tyrode’s buffered solution and incubated with 5 
 
m
 
g/ml IgE
for 20 min at 4
 
8
 
C to saturate IgE binding to Fc
 
e
 
RI, followed by
staining with FITC-conjugated rat anti–mouse IgE (Serotec Ltd.)
for 20 min at 4
 
8
 
C. Flow cytometric analyses were performed
with FACSCalibur™ (Becton Dickinson), and peritoneal mast
cells were sorted as c-kit and IgE-positive cells as described (18).
 
ELISA Determinations for Blood Histamine.
 
Blood was collected
from subocular plexus of mice into microcentrifuge tubes con-
taining EDTA on ice at 5 min after antigen challenge, and plasma
was prepared. Histamine in the plasma samples was quantified us-
ing ELISA plates (ICN Pharmaceuticals, Inc.) according to the
manufacturer’s instructions.
 
Histological Study.
 
Mice were killed by cervical dislocation.
Their tissues were removed and fixed in 10% (vol/vol) neutral
buffered formalin and then embedded in paraffin. The specimens
were sectioned at 3 
 
m
 
m and stained with toluidine blue at pH
4.0. The number of mast cells/mm
 
2
 
 was determined under a light
microscope. A ‘degranulated’ mast cell was defined as a cell
showing extrusion of 
 
.
 
10% cell granules.
 
Statistical Analysis.
 
Statistical differences were calculated using
Student’s 
 
t
 
 test or Fisher’s test. P , 0.05 was considered significant.
Results and Discussion
Modulation of IgG1-mediated Systemic Anaphylaxis in
FcgRIIB2/2 or FcgRIII2/2 Mice. Bocek et al. (7) reported
that coclustering of FcgRIIB and FcgRIII on RBL-2H3
cells did not lead to stimulation of the cells, suggesting a pos-
sible inhibitory role of FcgRIIB in this process. In addition,
in vitro observations by Daëron et al. (12) demonstrated that
mast cell secretory responses triggered by FceRI may be
controlled by FcgRIIB/III. Moreover, the regulatory role of
FcgRIIB was also observed in the cellular activation process
via B cell receptors (19–21) and T cell receptors (13; for re-
view see reference 14). Our previous studies using gene-tar-
geted mice had demonstrated the role of FcgRIIB in modu-
lating IgG1-mediated passive cutaneous anaphylaxis (11). To
establish the generality of those in vivo observations, we in-
vestigated IgG1-mediated passive systemic anaphylaxis in
FcgRIIB2/2 and FcgRIII2/2 mice. We chose to evaluate a
passive rather than active model in our studies because
FcgRIIB2/2 mice display enhanced humoral immune re-
sponses (11) that could complicate the comparison and inter-
pretation of the anaphylactic responses. To elicit the anaphy-
lactic response, mice were injected intravenously with IgG1
specific for TNP, followed by intravenous administration of1575 Ujike et al.
TNP-OVA 30 min later. Fig. 1 A shows that FcgRIIB2/2
mice developed an enhanced IgG1-dependent passive sys-
temic anaphylactic response as compared with passively sen-
sitized wild-type controls challenged with TNP-OVA. In
wild-type mice, the decrease in core temperature was also
transient, reaching a nadir z15 min after induction, whereas
the drop in temperature of FcgRIIB2/2 mice persisted for
more than 30 min without returning to baseline.
The mAb 2.4G2 is specific for the extracellular domains of
murine FcgRIIB and FcgRIII (22). 2.4G2 induces a degranu-
lative response in BMMC, which is enhanced in cells derived
from FcgRIIB2/2 mice (11). This enhancement is apparent
in vivo as well as shown in Fig. 1 B, where the decrease in
core temperature after administration of 2.4G2 was more pro-
nounced in FcgRIIB2/2 mice than in control mice. These
results indicate that FcgRIIB on effector cells, such as mast
cells, inhibits the systemic anaphylaxis elicited via FcgRIII.
In contrast to the enhanced responses in FcgRIIB2/2 mice
described above (Fig. 1, A and B), both FcgRIII2/2 mice and
FcRg2/2 mice failed to develop IgG1-mediated passive
systemic anaphylaxis (Fig. 1 C), directly establishing that
IgG1-mediated anaphylaxis is triggered through FcgRIII,
as was indirectly suggested by others (9, 10).
Enhancement of IgE-mediated Anaphylaxis in FcgRIIB2/2
Mice. As IgE immune complexes can bind with low affin-
ity to FcgRII and III in vitro, we next induced passive
systemic anaphylaxis upon anti-TNP IgE adoptive transfer
and TNP-OVA administration into FcgRIIB2/2 mice.
IgE-mediated systemic anaphylaxis was significantly enhanced
in FcgRIIB2/2 mice, as assessed by changes in core tem-
perature (Fig. 2 A), heart rate (Fig. 2 B), and augmented
hemorrhage in the ileum villi (Fig. 2 C). These results indi-
cate that IgE/FceRI-mediated anaphylaxis is facilitated by
the deletion of FcgRIIB in vivo without any apparent in-
volvement of IgG-immune complexes.
Systemic anaphylaxis can result in a fatal outcome. In
Figure 1. IgG1-mediated or 2.4G2-induced systemic anaphylaxis in FcgRIIB2/2 or
FcgRIII2/2 mice. (A) Changes in rectal temperature of mice during IgG1-induced
systemic anaphylaxis. 10 wild-type (h) and 8 FcgRIIB2/2 animals (j) received 200
mg i.v. anti-TNP IgG1. All of the animals received 1.0 mg i.v. TNP4-OVA 30 min
later. Six additional wild-type (s) as well as FcgRIIB2/2 mice (d) received 200 mg
IgG1 and then 1.0 mg OVA as controls. The monitoring of rectal temperature was
started at the time of antigen injection. Data are shown as mean 6 SD. **P , 0.01. (B)
Changes in rectal temperature in response to intravenous injection of 10 mg rat mAb
2.4G2 in 14 wild-type mice (h) and 8 FcgRIIB2/2 mice (j). As controls, five wild-
type (s) as well as four FcgRIIB2/2 mice (d) received 10 mg normal rat IgG. Data are
shown as mean 6 SD. **P , 0.01. (C) Changes in rectal temperature during IgG1-
induced systemic anaphylaxis in three FcRg2/2 (d), five FcgRIII2/2 (j), or three
wild-type mice (h). For the induction, mice received 400 mg i.v. anti-TNP IgG1 and
then received 4.0 mg i.v. TNP4-OVA 30 min later. Data are shown as mean 6 SD. *P ,
0.05; **P , 0.01, compared with wild-type mice.1576 Regulation of IgE-mediated Anaphylaxis by Fcg Receptors
mice, this mortality has been shown to be associated with
IgG1 and FcgRIII (9). As shown in Table I, we observed
mortality as a consequence of the anaphylactic response
only in FcgRIIB2/2 mice upon administration of either
IgG1 or IgE and the corresponding antigen, or 2.4G2.
These results confirm that either IgE- or IgG-induced sys-
temic anaphylaxis is indeed augmented in FcgRIIB2/2
mice, as assessed by mortality during anaphylaxis.
Neither FceRI Expression Level nor Mast Cell Density Is Up-
regulated in FcgRIIB2/2 Mice. These unexpected observa-
tions for IgE-mediated anaphylaxis prompted us to examine
whether deletion of FcgRIIB influenced FceRI expression
levels on effector cells. We confirmed by flow cytometric
analysis that the expression level of FceRI on BMMC from
FcgRIIB2/2 mice was comparable to the level on wild-
type BMMC (data not shown). In addition, we could not
demonstrate any significant difference in the expression
levels of FceRI on mast cells after IgE-induced upregula-
tion in vitro or in vivo (Fig. 3, A and B). As shown in Fig.
3 A, BMMC derived from either from FcgRIIB2/2 or
wild-type mice displayed the same level of upregulation of
FceRI in response to IgE (18). Similarly, peritoneal mast
cells isolated from FcgRIIB2/2 and wild-type mice 24 h
after intravenous administration of 20 mg IgE had equiva-
lent levels of FceRI (Fig. 3 B). Histopathological examina-
tions indicated that the density and morphology of mast
cells in ear, abdominal skin, and trachea from the mutant
Figure 3. Expression levels of FceRI on BMMC and peritoneal mast
cells after induction with IgE. (A) FceRI upregulation in vitro. BMMC
were cultured for 4 d in the presence of 0.1 or 5 mg/ml IgE or 5 mg/ml
2.4G2. Mean values of FceRI expression levels were assessed by flow cyto-
metric measurement of IgE binding. (B) FceRI levels in in vivo mast cells.
FcgRIIB2/2 (d) and wild-type (s) mice received 20 mg i.v. IgE, and 24 h
later, mean fluorescence intensities of IgE binding on peritoneal mast cells
were compared by flow cytometry as described in Materials and Methods.
Figure 2. IgE-mediated systemic anaphylaxis in FcgRIIB2/2 mice. (A)
Changes in rectal temperature during IgE-mediated systemic anaphylaxis.
29 wild-type (WT; h) and 24 FcgRIIB2/2 animals (j) received 20 mg i.v.
anti-TNP IgE. All of the animals received 1.0 mg i.v. TNP4-OVA 24 h
later. Three additional wild-type (s) as well as FcgRIIB2/2 mice (d) re-
ceived IgE and then OVA. The monitoring of rectal temperature was
started at the time of antigen injection. Data are shown as mean 6 SD.
**P , 0.01. (B) Changes in heart rate during IgE-mediated systemic ana-
phylaxis in three FcgRIIB2/2 (j) and three wild-type (h) mice. The in-
duction protocols were the same as in A. As controls, three wild-type
mice (s) received OVA. Note the transient rise maximizing z1 min af-
ter TNP-OVA injection in wild-type mice and the gradual decrease dur-
ing the 25 min after induction, in contrast to the changes in FcgRIIB2/2
mice, showing no transient rise and continuous decrease in heart rate. *P ,
0.05; **P , 0.01, compared with wild-type mice. (C) Increased hemor-
rhage in ileum villi during IgE-mediated systemic anaphylaxis in
FcgRIIB2/2 mice. 1 h after the anaphylaxis induction, mice were killed,
and ileum samples were observed under light microscopy. Hemorrhage in
tips of microvilli was evident in FcgRIIB2/2 mice. Magnification 40.1577 Ujike et al.
mice were not significantly different from those in wild-
type mice (data not shown).
Increases in the Number of Degranulated Mast Cells and in
Blood Histamine Levels after IgE-mediated Anaphylaxis Induc-
tion. The mechanism by which FcgRIIB2/2 mice aug-
mented IgE-mediated anaphylaxis was examined by deter-
mining the activation of effector cells in these animals as
compared with their wild-type counterparts. Blood hista-
mine levels were measured after the induction of anaphy-
laxis in FcgRIIB2/2 and wild-type mice. As shown in Fig.
4 A, blood obtained both from wild-type or FcgRIIB2/2-
sensitized animals 5 min after challenge with antigen or
2.4G2 revealed increased histamine concentrations. The
histamine levels seen in FcgRIIB2/2-challenged mice were
consistently higher in response to IgE, IgG1, or 2.4G2
stimulation than in control mice, suggesting that the en-
hanced anaphylaxis in FcgRIIB2/2 mice could be inter-
preted in part by accelerated activation of mast cells in the
mutant animals. To directly demonstrate enhanced degran-
ulation, lung samples from FcgRIIB2/2 or wild-type mice
were removed before and 30 min after the induction of
IgG-mediated passive systemic anaphylaxis and examined
histopathologically. As shown in Fig. 4 B and E, mast cells
around bronchi in FcgRIIB2/2 mice displayed quantita-
tively more degranulation than comparable samples taken
from wild-type mice subjected to similar treatment.
Conclusions. Although Takizawa et al. (6) demonstrated
that FcgRIIB and FcgRIII act as low-affinity receptors for
Figure 4. Enhanced mast cell
activation in FcgRIIB2/2 mice
during systemic anaphylaxis. (A)
Elevated plasma histamine in
FcgRIIB2/2 mice during IgE- or
IgG1-mediated or 2.4G2-induced
systemic anaphylaxis. Plasma hista-
mine 5 min after antigen challenge
in each wild-type (1/1) and mu-
tant (2/2) mouse is presented as
mM. Horizontal bars, mean values.
(B) Enhanced degranulation of
lung mast cells in FcgRIIB2/2
mice during IgE-mediated sys-
temic anaphylaxis. Densities of
lung mast cells were calculated by
counting the cells in four different
sections derived from two mice
under light microscopy. The re-
sults are expressed as mean 6 SD.
The densities of control (before
induction), wild-type (WT), and
FcgRIIB2/2 mice were not signif-
icantly different. However, the
number of degranulated mast cells
(closed columns) was significantly
higher in FcgRIIB2/2 mice (P ,
0.005, Fisher’s test). (C–E) Photo-
graphs of lung mast cells in wild-
type mice before anaphylaxis in-
duction (C), and in wild-type (D)
or FcgRIIB2/2 (E) mice after in-
duction. Toluidine blue staining.
Magnification 1,000.
Table I. Mortality During Systemic Anaphylaxis
Inductiona
Death ratesb Times until death (min)
Wild type FcgRIIB2/2 Wild type FcgRIIB2/2
IgE 0/29 (0%) 5/29 (17%)* N.A. 5, 20, 25, 40, 40
IgG1 0/10 (0%) 2/10 (20%)§ N.A. 20, 30
2.4G2 0/14 (0%) 6/14 (43%)‡ N.A. 10, 25, 25, 30, 30, 30
aSystemic anaphylaxis was induced with anti-TNP IgG1 transfer and TNP-OVA injection, 2.4G2 administration, or anti-TNP IgE transfer and
TNP-OVA injection.
bStatistical analyses were performed between wild-type and FcgRIIB2/2 mice using Fisher’s test: *P , 0.05; ‡P , 0.01; §NS.
N.A., not applicable.1578 Regulation of IgE-mediated Anaphylaxis by Fcg Receptors
IgE on cultured mast cells and macrophages in vitro, the
physiological significance of this interaction between IgE
and FcgRIIB/III has not been established. The consequence
of a low-affinity interaction between IgE and FcgRs in
vivo would result in IgE immune complexes binding not
only to FceRI but also to FcgRIIB/III on those cells and
potentially modulating mediator release. Dombrowicz et al.
(4) have shown that although BMMC from FceRI2/2
mice can bind IgE immune complexes via FcgRIIB/III in
vitro, the abrogation of IgE-mediated systemic anaphylaxis
in vivo by deletion of FceRI would indicate that the inter-
action of IgE with FcgRs is not significant. However, an
alternative explanation for their data is suggested by the
present studies, as the FceRI2/2 strain retains FcgRIIB as
well as FcgRIII on its mast cells (4). Based on our data, we
propose that the IgE immune complex–mediated response
would represent the sum of three components, i.e., an
FceRI-mediated major positive factor, an FcgRIIB nega-
tive response, and an FcgRIII-mediated positive compo-
nent, respectively. When the FceRI component had been
lost, the sum of the remaining FcgRIIB and FcgRIII com-
ponents would be negligible. Our present results predict
that a sum of the components of FceRI and FcgRIIB
would be a positive, although diminished, response. This
prediction is supported by the IgE-mediated anaphylactic
response in FcgRIII2/2 mice. As shown in Fig. 5 A,
FcgRIII2/2 mice indeed show a decreased response in IgE-
mediated systemic anaphylaxis. Moreover, we found that
blocking of FcgRIIB by preadministration of 2.4G2 re-
sulted in an enhanced response in IgE-mediated systemic
anaphylaxis in FcgRIII2/2 mice (Fig. 5 B). Taken together,
these results support the conclusion that FcgRIIB attenu-
ates IgE-mediated anaphylactic responses triggered by FceRI
or FcgRIII.
Further support for the role of FcgRIIB in modulating
the IgE-mediated response comes from studies in Src ho-
mology 2–containing inositol phosphatase (SHIP)-deficient
mice (23). This inositol polyphosphate phosphatase is re-
cruited to FcgRIIB upon cross-linking with an immunore-
ceptor tyrosine-based activation motif (ITAM)-containing
activation receptor through its SH2 (Src homology 2) do-
main and leads to the hydrolysis of phosphatidylinositol
3,4,5-trisphosphate, with release of Bruton’s tyrosine kinase
and phospholipase Cg from the inner leaflet of the cell mem-
brane (24). The net result of this pathway is the termination
of calcium influx, with subsequent inhibition of activation re-
sponses (20, 21, 25). Mast cells derived from SHIP-deficient
mice display a hyperresponsive IgE phenotype similar to the
response seen in FcgRIIB2/2 mice (26). Thus, functional un-
coupling of FcgRIIB from its signaling pathway results in
similar phenotype deletion of the receptor itself.
The observations presented here support the hypothesis
that IgE-mediated activation is modulated by inhibitory re-
ceptors like FcgRIIB. Perturbation of an inhibitory path-
way would be predicted to render mast cells more sensitive
to IgE activation and could account for some atopic pheno-
types. Upregulation of FcgRIIB or its constitutive engage-
ment would result in desensitization of mast cells to IgE
triggering and reversal of the atopic state.
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